1. Please check and comment entries here.
Table of Contents

    Topic review

    Medicinal-Plant Extracts against Chikungunya Virus

    View times: 13
    Submitted by: Nam Weng Sit

    Definition

    The lack of specific treatment for chikungunya fever makes the need for anti-chikungunya virus agents more crucial. This study was conducted to evaluate 132 extracts obtained by sequential solvent extraction from 21 medicinal plants for cytopathic effect inhibitory activity using virus-infected Vero cells in two different sample introduction modes. Among the extracts, 42 extracts (31.8%) from 12 plants in the concurrent mode and three extracts (2.3%) from a plant in the non-concurrent mode displayed strong cytopathic effect inhibitory activity (cell viability ≥70%). Viral load quantification analysis unveiled that the extracts of Clinacanthus nutans (chloroform, ethyl acetate, and ethanol), Hydrocotyle sibthorpioides (ethanol), and Ocimum americanum (ethanol and methanol) hindered the release of viral progeny from the infected cells while the extracts of Ficus deltoidea (ethanol), Gynura bicolor (water), H. sibthorpioides (water), and O. americanum (chloroform and ethyl acetate) blocked the entry of virus into the cells. The extracts of Diodella sarmentosa (ethyl acetate), Diplazium esculentum (chloroform, ethyl acetate, and ethanol), and G. bicolor (ethanol) possessed virucidal effect and caused 5.41-log to 6.63-log reductions of viral load compared to the virus control. The results indicate that these medicinal plants are potential sources of anti-chikungunya virus agents that have varied modes of action. 

    1. Introduction

    Chikungunya virus is an enveloped, single-stranded, positive-sense RNA virus belonging to the genus Alphavirus of the Togaviridae family. It is an arthropod-borne virus causing chikungunya fever in humans [1]. The virus was first isolated from a febrile patient in the southern Tanzania in 1952–1953 [2]. Subsequent outbreaks of chikungunya infection have largely been confined to the countries in sub-Saharan Africa and Asia [3]. However, over the last two decades, the virus has caused devastating epidemics in India, Southeast Asia and Pacific Islands, and islands in the Indian Ocean, leading to over six million cases of infection [4]. Since 2013, the virus has spread and established its autochthonous transmission in the Western Hemisphere, resulting in over two million suspected cases being reported in almost 50 countries in the Americas. The virus has been documented in 114 countries and territories [5]. Recent analysis indicates that this virus caused an average yearly loss of over 106,000 disability-adjusted life years for the period 2010–2019 [6]. According to the surveillance done by the European Centre for Disease Prevention and Control, at least 170,000 cases of chikungunya fever occurred globally in the year 2020 [7]. Malaysia recorded 2556 cases in the same year and about 86% of the cases happened in the states of Perak and Penang [8].
    Chikungunya virus is mainly transmitted via a bite by the infected mosquitoes Aedes aegypti and Aedes albopictus. The virus can cross the placenta and goes into the fetus in the vertical transmission mode, which results in higher rates of infant morbidity [9]. Upon an acute infection, 80–97% of patients are symptomatic [10] and their clinical manifestations include arthralgia or polyarthralgia, high fever, headache, myalgia, skin rashes, joint swelling, and nausea [11]. Although the mortality rate is relatively low (0.07%), polyarthralgia can persist in the patients for several months or even years after resolution of the acute phase of infection, this being the most common long-term sequel of chikungunya virus infection [6][12]. Presently, patients with chikungunya fever are treated with antipyretic, analgesic, or anti-inflammatory drugs for symptomatic relief [5]. While efforts have been pursued to develop safe and effective vaccines for prophylaxis and antiviral drugs for therapeutics [13][14][15], currently there is no licensed vaccine or drug available against chikungunya virus. This emphasizes the need for more antiviral drugs.
    According to the World Health Organization estimates, approximately 80% of the world population use medicinal plants for some aspects of primary health care [16]. Plants are able to produce arrays of phytochemicals with diverse chemical structures such as alkaloids, terpenoids, essential oils, flavonoids, and polyphenols. Many of these phytochemicals, which are derived from the different pathways of secondary metabolism, serve as chemical weapons for the plants against microbial infections, predations by insects and herbivores. They may also be indicators of environmental stress [17]. These phytochemicals are also found to have various biological activities which are beneficial to human health. The antiviral activities of medicinal plants have been well documented against human immunodeficiency [18][19], influenza, herpes simplex [20][21], hepatitis [21][22], and dengue viruses [23][24]. A total of 17 extracts are reported to have anti-chikungunya virus activity from the screenings of 84 medicinal or endemic plants [25][26]. Epigallocatechin gallate derived from Camellia sinensis and curcumin from Curcuma longa are reported to prevent chikungunya virus from attachment to cells [27][28] while harringtonine from Cephalotaxus harringtonia is able to block the replication of the virus in vitro [29].
    Twenty-one species of medicinal plants belonging to 19 families were selected for the present study and extracted sequentially using six solvents of increasing polarity. The medicinal or folkloric uses of these medicinal plants are shown in Table 1. The phytochemicals are segregated into different extractants based on their polarity and solubility during sequential solvent extraction [30]. Less polar solvents such as hexane and chloroform could extract alkaloids, coumarins, fatty acids, and terpenoids while more polar solvents such as ethyl acetate, ethanol, methanol, and water could yield saponins, tannins, flavones, polyphenols, terpenoids, anthocyanins, polypeptides, and lectins from plants [31]. The objectives of this study were to evaluate the plant extracts for cytopathic effect inhibitory activity using chikungunya virus-infected African monkey kidney epithelial (Vero) cells in two different sample introduction modes, i.e., concurrent and non-concurrent modes. In the concurrent mode, the plant extracts and the virus inoculum were introduced simultaneously to the cells whereas for the non-concurrent mode, the cells were incubated with the extracts for 24 h before the addition of the virus inoculum. The modes of action of the selected active extracts were assessed based on the quantification of viral load using real-time reverse-transcriptase polymerase chain reaction (RT-PCR). The results of this study highlighted that medicinal plant extracts possess anti-chikungunya virus activity with varied modes of action.
    Table 1. Details and uses of selected medicinal plants.
    Plant Name Family Vernacular Name Part Used Medicinal or Folkloric Uses Voucher Number
    Ailanthus triphysa (Dennst.) Alston Simaroubaceae White siris Leaf Hypertension, bronchitis, dysentery [32] UTAR/FSC/11/004
    Archidendron jiringa (Jack) I.C.Nielsen Leguminosae Djengkol bean Seed Bladder stones, hypertension, diabetes [33] Nil
    Arundina graminifolia (D.Don) Hochr. Orchidaceae Grass orchid Leaf Snake bites, rheumatism, stomachache [34] UTAR/FSC/10/011
    Azadirachta indica A.Juss. Meliaceae Neem Leaf Leprosy, skin ulcers, biliousness, epistaxis, eye problem, anorexia, intestinal worms [35] UTAR/FSC/11/001
    Basella alba L. Basellaceae Ceylon spinach, Malabar spinach Leaf Constipation, liver and urinary diseases, catarrh, gonorrhea, boils, sore throat, hypertension, burns [36] UTAR/FSC/10/014
    Beta vulgaris L. Amaranthaceae Beetroot Root Dandruff, decreased libido, constipation, joint pain [37] Nil
    Clinacanthus nutans (Burm.f.) Lindau Acanthaceae Sabah snake grass Leaf Diabetes, dysentery, eye diseases, skin rashes, allergic responses, insect and snake bites [38] UTAR/FSC/11/003
    Curcuma longa L. Zingiberaceae Turmeric Rhizome Stomachic and intestinal diseases, arthritis, gall stones, emmenagogue, bruise, as a tonic [39] Nil
    Diodella sarmentosa (Sw.) Bacigalupo & Cabral ex Borhidi Rubiaceae Tropical buttonweed Leaf and stem Ulcers, snake bite, rheumatic inflammatory disorders, venereal diseases [40] UTAR/FSC/10/018
    Diplazium esculentum (Retz.) Sw. Athyriaceae Vegetable fern Leaf and stem Constipation, hypertension [41] UTAR/FSC/10/023
    Ficus deltoidea Jack Moraceae Mistletoe fig Leaf Wounds, rheumatism, sores, as an after-birth tonic [42] UTAR/FSC/10/021
    Gynura bicolor (Roxb. ex Willd.) DC. Compositae Okinawa spinach Leaf Blood circulation improvement, diabetes, dysmenorrhea, hemoptysis, post-labor recovery [43] UTAR/FSC/11/005
    Homalocladium platycladum (F.Muell.) L.H.Bailey. Polygonaceae Centipede plant Stem Skin swelling, sores, insect and snake bites, fracture injuries, fever [44] UTAR/FSC/10/017
    Hydrocotyle sibthorpioides Lam. Araliaceae Lawn marsh pennywort Whole plant Cough, cold, fever, zoster, eczema, hepatitis, jaundice [45] UTAR/FSC/10/019
    Manilkara zapota (L.) P.Royen Sapotaceae Sapodilla, Ciku Fruit Diarrhea, pulmonary complaints [46] Nil
    Ocimum americanum L. Lamiaceae Hoary basil Leaf Fever, colds, dysentery, toothache, migraine [47] UTAR/FSC/10/013
    Parkia speciosa Hassk. Leguminosae Stink bean Seed and pod Urinary infections, diabetes, loss of appetite [48] UTAR/FSC/10/015
    Petroselinum crispum (Mill.) Fuss Apiaceae Parsley Leaf and stem Skin diseases, eczema, hypertension, diabetes, nosebleed, constipation pain, baldness [49] UTAR/FSC/10/024
    Salacca zalacca (Gaertn.) Voss Arecaceae Salak Fruit Diabetes [50] Nil
    Sechium edule (Jacq.) Sw. Cucurbitaceae Chayote Leaf and stem Kidney stones, hypertension [51] UTAR/FSC/10/022
    Strobilanthes crispus (L.) Blume Acanthaceae Yellow strobilanthus, “kejibeling” Leaf Kidney stones, enhance immune system [52] UTAR/FSC/10/020

    2. Results and Discussion

    A total of 132 extracts obtained from 21 plant species were subjected to the antiviral activity screening against the chikungunya virus. As six different solvents were used, each extractant yielded 22 extracts. The ability of an extract to protect Vero cells from the cytopathic effect caused by the virus was used as a measurement of antiviral activity for the extract. As an extract is a mixture of many phytochemicals extracted from a particular plant part, it may contain compounds that are toxic to Vero cells. Thus, it is necessary to determine the non-toxic concentrations for use in the cytopathic effect inhibitory assay. As such, a standardized test concentration range of an extract is not feasible.
    In order to express and classify the cytopathic effect inhibitory activity of an extract, three scales were established based on percentage of cell viability, these being strong inhibitory activity when the cell viability is ≥70%, intermediate inhibitory activity when the cell viability is 31–69%, and weak inhibitory activity when the cell viability is ≤30%. The inhibitory activity for each extract is shown in Table 2. Forty-two extracts (31.8%) were found to have strong inhibitory activity in the concurrent mode compared to only three extracts (2.3%) in the non-concurrent mode. These extracts were derived from 12 medicinal plants, i.e., Azadirachta indica, Clinacanthus nutans, Diodella sarmentosa, Diplazium esculentum, Ficus deltoidea, Gynura bicolor, Hydrocotyle sibthorpioides, Homalocladium platycladum, Ocimum americanum, Petroselinum crispum, Sechium edule, and Strobilanthes crispus. The results indicate that the cytopathic effect inhibitory activity was dependent on plant species and sample introduction mode. The results also suggest that phytochemicals in the extracts could exert an inhibitory effect against the virus in the concurrent mode but lost their activity in the non-concurrent mode. The exposure of Vero cells to the extracts for 24 h before the addition of virus inoculum could result in the metabolism of active phytochemicals into metabolites devoid of inhibitory activity. An exception was noted for the three extracts with strong inhibitory activity in the non-concurrent mode. They were ethyl acetate, ethanol, and methanol extracts of F. deltoidea. The corresponding cell viabilities in the concurrent mode were 66.8% ± 4.2% at 10 µg/mL, 71.9% ± 5.3% at 40 µg/mL, and 1.5% ± 2.9% at 40 µg/mL, respectively, and increased to 76.5% ± 4.1% (p = 0.046), 90.3% ± 0.8% (p = 0.024), and 79.8% ± 6.7% (p < 0.001), respectively, in the non-concurrent mode, suggesting that the metabolites produced (in the non-concurrent mode) may have stronger activity than their parent compounds.
    Table 2. Classification of cytopathic effect inhibitory activity of each medicinal plant extract for the concurrent and non-concurrent modes.
    Plant Part Concurrent Mode Non-Concurrent Mode
      Extract # HX CF EA EN MN WT HX CF EA EN MN WT
    Ailanthus triphysa Leaf W W W W W W W W W W W W
    Archidendron jiringa Seed W I W W W W W I W W W W
    Arundina graminifolia Leaf W W W W W W W I I W W W
    Azadirachta indica Leaf I S S S S W W W W W W W
    Basella alba Leaf W I W W W W I I I W W W
    Beta vulgaris Root W W W W W W W W W W W W
    Clinacanthus nutans Leaf W S S S S W W W W W I W
    Curcuma longa Rhizome W I W W W I W W W W W W
    Diodella sarmentosa Leaf and stem W S S S W W W I W I W W
    Diplazium esculentum Leaf and stem W S S S S W W W W I W W
    Ficus deltoidea Leaf W S I S W W W I S S S W
    Gynura bicolor Leaf W S S S S S W W I W W W
    Homalocladium platycladum Stem W S S S I S W W I W W W
    Hydrocotyle sibthorpioides Whole plant W S I W S W W W W W W W
    Manilkara zapota Fruit W W W W W W W W W W W W
    Ocimum americanum Leaf I S S S S S W W W W W W
    Parkia speciosa Pod W I I W W W W W W W W W
    Parkia speciosa Seed W W W W W W W W W W W W
    Petroselinum crispum Leaf and stem W S S S W W W W W I W W
    Salacca zalacca Fruit W W W W W W W W W W W W
    Sechium edule Leaf and stem W S S S W W W W I I W W
    Strobilanthes crispus Leaf W S I S S W W W W W W W
    # HX: hexane; CF: chloroform; EA: ethyl acetate; EN: ethanol; MN: methanol; WT: water. S: strong inhibitory activity when cell viability ≥70%; I: intermediate inhibitory activity when cell viability is 31–69%; W: weak inhibitory activity when cell viability ≤30%.
     
    The data in Figure 1 indicate that extractants such as chloroform, ethyl acetate, ethanol, and methanol resulted in higher activity compared to hexane and water, both in the concurrent mode and non-concurrent mode. The type of solvent used to extract phytochemicals from plants is an important contributing factor to the results of the bioassay. Phytochemicals of a plant part are solubilized in an extractant based on their polarity [30].
    Figure 1. Classification of medicinal plant extracts according to their cytopathic effect inhibitory activity against chikungunya virus in (A) concurrent mode and (B) non-concurrent mode. The number of extracts for each extractant is 22. The inhibitory activity is measured based on the percentage of viable cells protected by an extract from the cytopathic effect caused by the virus. Strong: cell viability ≥70%; intermediate: cell viability 31–69%; weak: cell viability ≤30%.
    Among the 45 extracts which exhibited strong inhibitory activity, 20 extracts of seven plants from the concurrent mode and one extract of a plant from the non-concurrent mode were able to protect ≥90% of Vero cells from the cytopathic effect caused by the virus, as shown in Figure 2. These 21 extracts are of great potential for further drug developments. A wide half-maximal effective concentration (EC50) range was observed for these extracts, ranging from 1.33 µg/mL for the ethanol extract of O. americanum to 394.0 µg/mL for the water extract of H. sibthorpioides (Table 3). Consequently, the selectivity indices for these extracts ranged from 2.62 to 170.2. The indices for the ethanol extract of S. edule and the water extract of H. sibthorpioides could not be calculated as no significant cytotoxicity (p > 0.05) was recorded.
    Figure 2. Viability of Vero cells infected by chikungunya virus and treated with different extracts of medicinal plants. (A) Clinacanthus nutans; (B) Diodella sarmentosa; (C) Diplazium esculentum; (D) Ficus deltoidea; (E) Gynura bicolor; (F) Hydrocotyle sibthorpioides; (G) Ocimum americanum; (H) Sechium edule. All plants are shown for the concurrent mode except Ficus deltoidea, which is in the non-concurrent mode. The cell viability is measured using the neutral red uptake assay. The notated asterisks (*) denote significant differences (p < 0.05) among concentrations within an extract by one-way ANOVA.
    Table 3. Selectivity indices and viral RNA copy numbers for the selected active medicinal plant extracts against chikungunya virus.
    Plant Extract Half-Maximal Cytotoxic Concentration, CC50 (µg/mL) Mode ^ Half-Maximal Effective Concentration, EC50 (µg/mL) Selectivity Index (= CC50/EC50) Viral RNA Copy Number (Molecules/µL) Log Reduction #
    Clinacanthus nutans Chloroform 602.67 ± 9.29 C 120.67 ± 4.62 4.99 7.75 × 109 ± 1.69 × 109 * 0.89
    Ethyl acetate 133.00 ± 9.17 C 9.93 ± 0.91 13.39 1.68 × 1010 ± 0.51 × 1010 * 0.55
    Ethanol >640 C 31.30 ± 0.95 >20.45 8.72 × 109 ± 1.25 × 109 * 0.83
    Diodella sarmentosa Ethyl acetate 203.33 ± 6.11 C 8.33 ± 0.57 24.40 1.83 × 105 ± 1.07 × 105 * 5.51
    Diplazium esculentum Chloroform 99.00 ± 3.61 C 6.80 ± 0.26 14.56 4.23 × 104 ± 0.59 × 104 * 6.15
    Ethyl acetate 184.33 ± 9.24 C 14.07 ± 0.06 13.10 1.38 × 104 ± 0.62 × 104 * 6.63
    Ethanol 220.67 ± 1.53 C 14.30 ± 0.20 15.43 3.40 × 104 ± 1.02 × 104 * 6.24
    Methanol 461.00 ± 1.73 C 29.70 ± 0.60 15.52 1.12 × 109 ± 0.11 × 109 * 1.73
    Ficus deltoidea Ethanol >640 NC 15.20 ± 0.20 >42.10 4.42 × 106 ± 2.71 × 106 † 4.13
    Gynura bicolor Chloroform 117.67 ± 9.50 C 3.65 ± 0.06 32.21 3.50 × 109 ± 1.18 × 109 * 1.23
    Ethyl acetate 31.33 ± 4.16 C 1.91 ± 0.03 16.43 3.71 × 108 ± 2.90 × 108 † 2.21
    Ethanol 55.00 ± 3.46 C 3.62 ± 0.10 15.18 2.33 × 105 ± 0.58 × 105 * 5.41
    Water > 640 C 244.67 ± 4.73 >2.62 3.29 × 105 ± 1.78 × 105 † 5.26
    Hydrocotyle sibthorpioides Ethanol 610.33 ± 9.50 C 95.33 ± 2.47 6.40 4.01 × 1010 ± 1.54 × 1010 * 0.17
    Water - C 394.00 ± 6.93 - 4.39 × 105 ± 2.74 × 105 † 5.13
    Ocimum americanum Chloroform 86.33 ± 4.73 C 3.61 ± 0.11 23.92 5.50 × 105 ± 0.75 × 105 † 5.03
    Ethyl acetate 60.83 ± 2.02 C 1.37 ± 0.06 4.45 3.57 × 105 ± 0.26 × 105 † 5.22
    Ethanol 226.33 ± 9.87 C 1.33 ± 0.10 170.18 1.71 × 1010 ± 0.48 × 1010 * 0.54
    Methanol >640 C 21.93 ± 0.84 >29.18 7.81 × 109 ± 2.32 × 109 * 0.88
    Sechium edule Ethyl acetate 100.67 ± 9.29 C 2.71 ± 0.25 37.10 7.43 × 109 ± 2.79 × 109 * 0.90
    Ethanol - C 90.33 ± 0.28 - 1.14 × 1010 ± 0.16 × 1010 * 0.72
    Chloroquine - 16.33 ± 0.76 NC 9.05 ± 0.05 2.89 1.68 × 106 ± 0.49 × 106 * 4.55
    C 1.92 ± 0.13 ** 13.65 3.94 × 105 ± 0.70 × 105 † 5.18
    Virus inoculum - - - - - 6.25 × 105 ± 2.09 × 105 -
    Virus control - - - - - 5.96 × 1010 ± 3.33 × 1010 -
    Values are expressed as mean ± standard deviation (n = 3). ^ C: concurrent mode; NC: non-concurrent mode. # compared with virus control. * significantly different (p < 0.05) from the virus inoculum by independent-samples t-test. significantly different (p < 0.05) from the virus control by independent-samples t-test. ** significantly different (p < 0.001) from the non-concurrent mode by independent-samples t-test.
     
    In order to yield some indications of the antiviral mechanisms of the 21 extracts, quantification of the viral copy number in the experiments was performed using a real-time RT-PCR. The results are shown in Table 3. All extracts of C. nutans and S. edule, ethanol extract of H. sibthorpioides, and ethanol and methanol extracts of O. americanum produced a viral copy number similar to the virus control (p > 0.05), suggesting the virus was successfully replicated in the Vero cells but the release of the viral progeny was inhibited by these extracts, and this prevented the occurrence of cytopathic effect in the cells. In contrast, the viral copy numbers for the infected cells treated with the extracts of F. deltoidea (ethanol), G. bicolor (water), H. sibthorpioides (water), and O. americanum (chloroform and ethyl acetate) were not significantly different (p > 0.05) from the copy number of the viral inoculum. The results suggested that these extracts may work as a fusion inhibitor and block the entry of the virus into the cells. The virus was not able to replicate in the experiments and the copy number remained similar to that of the viral inoculum throughout the 72-h incubation period. The viral copy numbers for five extracts, i.e., ethyl acetate extract of D. sarmentosa, chloroform, ethyl acetate, and ethanol extracts of D. esculentum, and ethanol extract of G. bicolor, were significantly lower (p < 0.05) than that of the virus inoculum. These extracts caused 5.41-log to 6.63-log reductions of viral load compared to the virus control (Table 3) as quantified by real-time RT-PCR, suggesting the active phytochemicals in the extracts possessed a virucidal effect on the chikungunya virus. The viral copy number indicates that phytochemicals may have different modes of action against the virus, as illustrated by the extracts of H. sibthorpioides and O. americanum whereby these extracts could prevent the release of viral progeny and the entry of the virus into cells. Similarly, the extracts of G. bicolor could kill the virus, as well as block the virus from entry into the cells.
    Chloroquine, which was used as a positive control, is reported to interfere with the protonation of the endocytic vesicles thereby raising the endosomal pH and preventing the fusion of chikungunya virus to the host cell [53]. The EC50 value of chloroquine obtained for the non-concurrent mode (9.05 µg/mL or 17.5 µM) was significantly higher (p < 0.001) than the concurrent mode (1.92 µg/mL or 3.72 µM) (Table 3), suggesting that the metabolism of chloroquine in the Vero cells may have reduced its efficacy by producing non-active metabolites or metabolites with reduced efficacy against the chikungunya virus. The EC50 value (3.72 µM) obtained in this study was generally lower than the values (5.0–11 µM) reported in the literature, probably resulting from the types of cells and the virus strains used [54][55][56].
    To the best of our knowledge, this study constitutes the first report of the antiviral properties of the medicinal plants D. sarmentosa, D. esculentum, F. deltoidea, G. bicolor, H. platycladum, and S. edule. Azadirachta indica, popularly known as neem, has been extensively used in the Unani, Ayurveda, and Chinese traditional systems of medicine [35]. Raghavendhar et al. studied the water extract of the bark of A. indica against chikungunya virus and reported that the extract did not reduce the plaque formation in Vero cells [57]. In contrast, the current study shows that the chloroform, ethyl acetate, ethanol, and methanol extracts of the leaves of A. indica had strong cytopathic effect inhibitory activity against the virus (Table 2). For C. nutans, H. sibthorpioides, O. americanum, P. crispum, and S. crispus, the results of this study further strengthen the case for these plants as potential sources of antiviral compounds. The antiviral activity of C. nutans has well been documented against herpes simplex virus types 1 and 2 [58][59], human papillomavirus [60], and dengue virus [61]. The methanol extract and the asiaticoside isolated from H. sibthorpioides possess anti-dengue virus activity [62] and anti-hepatitis B virus activity [63], respectively. The dichloromethane and methanol extracts of O. americanum and the methanol extract of S. crispus displayed anti-herpes simplex virus activities [64][65]. The methanol extract of P. crispum has been reported to have inhibitory activity against the Sindbis virus, which like the chikungunya virus is an alphavirus [66]. Further studies need to be carried out to elucidate the identity of antiviral compounds in the active extracts, the inhibitory or virucidal potential for the isolated pure compounds, and the possible synergistic effects among the isolated compounds in targeting different mechanisms of the life cycle of chikungunya virus.

    3. Conclusions

    For this research 132 extracts from 21 medicinal plant species were evaluated for cytopathic effect inhibitory activity against the chikungunya virus using concurrent and non-concurrent sample introduction modes. The inhibitory effect of the extracts was dependent on plant species, extract concentration, type of extractant, and sample introduction mode. More extracts were found to have strong inhibitory activity in the concurrent mode than in the non-concurrent mode. Analysis of selected 21 extracts from eight plants with a strong inhibitory activity using real-time RT-PCR indicates that the active extracts targeted the chikungunya virus life cycle at different stages, including inhibition of virus entry into Vero cells, blocking the release of viral progeny from the cells, and virucidal effect on the virus. Some of the medicinal plants such as G. bicolor, H. sibthorpioides, and O. americanum even possessed multiple antiviral mechanisms. The bioactive compounds in the plant extracts could be isolated and characterized as lead compounds for potential pharmaceutical developments into anti-chikungunya virus drugs. The plant extracts could also be evaluated against other viruses such as dengue virus, which causes another endemic mosquito-borne disease in Malaysia. The results of this study reiterated the fact that medicinal plant extracts contain many phytochemicals with biological activities. Medicinal plants could be explored as an accessible and sustainable source of chemotherapeutic agents for the treatment of emerging or re-emerging viral diseases. More collaborative efforts are needed to pursue the exploration of medicinal plants for human health benefits.

    The entry is from 10.3390/plants10081658

    References

    1. Smith, D.W.; Mackenzie, J.S.; Frolov, I.V.; Weaver, S.C. Alphaviruses. In Clinical Virology, 4th ed.; Richman, D.D., Whitley, R.J., Hayden, F.G., Eds.; ASM Press: Washington, DC, USA, 2017; pp. 1347–1380.
    2. Ross, R.W. The Newala epidemic: III. The virus: Isolation, pathogenic properties and relationship to the epidemic. J. Hyg. 1956, 54, 177–191.
    3. Vairo, F.; Haider, N.; Kock, R.; Ntoumi, F.; Ippolito, G.; Zumla, A. Chikungunya: Epidemiology, pathogenesis, clinical features, management, and prevention. Infect. Dis. Clin. N. Am. 2019, 33, 1003–1025.
    4. Silva, L.A.; Dermody, T.S. Chikungunya virus: Epidemiology, replication, disease mechanisms, and prospective intervention strategies. J. Clin. Investig. 2017, 127, 737–749.
    5. Centers for Disease Control and Prevention. Chikungunya Virus. Available online: https://www.cdc.gov/chikungunya/index.html (accessed on 3 January 2021).
    6. Puntasecca, C.J.; King, C.H.; LaBeaud, A.D. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl. Trop. Dis. 2021, 15, e0009055.
    7. European Centre for Disease Prevention and Control. Communicable Disease Threats Report, Week 51, 13–19 December 2020. Available online: https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-13-19-december-2020-week-51 (accessed on 3 January 2021).
    8. Ministry of Health Malaysia. Kenyataan Akhbar Ketua Pengarah Kesihatan Malaysia Mengenai Situasi Semasa Deman Denggi, Zika Dan Chikungunya Di Malaysia—Minggu Ke 51/2020. Available online: https://www.moh.gov.my/index.php/database_stores/store_view_page/17/1734 (accessed on 3 January 2021). (In Malay)
    9. Ferreira, F.C.; da Silva, A.S.; Recht, J.; Guaraldo, L.; Moreira, M.E.; de Siqueira, A.M.; Gerardin, P.; Brasil, P. Vertical transmission of chikungunya virus: A systematic review. PLoS ONE 2021, 16, e0249166.
    10. Natrajan, M.S.; Rojas, A.; Waggoner, J.J. Beyond fever and pain: Diagnostic methods for chikungunya virus. J. Clin. Microbiol. 2019, 57, e00350-19.
    11. Tanabe, I.S.B.; Tanabe, E.L.L.; Santos, E.C.; Martins, W.V.; Araújo, I.M.T.C.; Cavalcante, M.C.A.; Lima, A.R.V.; Câmara, N.O.S.; Anderson, L.; Yunusov, D.; et al. Cellular and molecular immune response to chikungunya virus infection. Front. Cell. Infect. Microbiol. 2018, 8, 345.
    12. Van Aalst, M.; Nelen, C.M.; Goorhuis, A.; Stijnis, C.; Grobusch, M.P. Long-term sequelae of chikungunya virus disease: A systematic review. Travel Med. Infect. Dis. 2017, 15, 8–22.
    13. Powers, A.M. Vaccine and therapeutic options to control chikungunya virus. Clin. Microbiol. Rev. 2017, 31, e00104-16.
    14. Gao, S.; Song, S.; Zhang, L. Recent progress in vaccine development against chikungunya virus. Front. Microbiol. 2019, 10, 2881.
    15. Hucke, F.I.L.; Bugert, J.J. Current and promising antivirals against chikungunya virus. Front. Public Health 2020, 8, 618624.
    16. World Health Organization. Guidelines on the Conservation of Medicinal Plants; International Union for the Conservation of Nature: Geneva, Switzerland, 1993; pp. 1–38.
    17. Zaynab, M.; Fatima, M.; Abbas, S.; Sharif, Y.; Umair, M.; Zafar, M.H.; Bahadar, K. Role of secondary metabolites in plant defense against pathogens. Microb. Pathog. 2018, 124, 198–202.
    18. Prinsloo, G.; Marokane, C.K.; Street, R.A. Anti-HIV activity of southern African plants: Current developments, phytochemistry and future research. J. Ethnopharmacol. 2018, 210, 133–155.
    19. Salehi, B.; Kumar, N.V.A.; Şener, B.; Sharifi-Rad, M.; Kılıç, M.; Mahady, G.B.; Vlaisavljevic, S.; Iriti, M.; Kobarfard, F.; Setzer, W.N.; et al. Medicinal plants used in the treatment of human immunodeficiency virus. Int. J. Mol. Sci. 2018, 19, 1459.
    20. Akram, M.; Tahir, I.M.; Shah, S.M.A.; Mahmood, Z.; Altaf, A.; Ahmad, K.; Munir, N.; Daniyal, M.; Nasir, S.; Mehboob, H. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review. Phytother. Res. 2018, 32, 811–822.
    21. Mohan, S.; Elhassan Taha, M.M.; Makeen, H.A.; Alhazmi, H.A.; Al Bratty, M.; Sultana, S.; Ahsan, W.; Najmi, A.; Khalid, A. Bioactive natural antivirals: An updated review of the available plants and isolated molecules. Molecules 2020, 25, 4878.
    22. Geng, C.A.; Chen, J.J. The progress of anti-HBV constituents from medicinal plants in China. Nat. Prod. Bioprospect. 2018, 8, 227–244.
    23. Saleh, M.S.M.; Kamisah, Y. Potential medicinal plants for the treatment of dengue fever and severe acute respiratory syndrome-coronavirus. Biomolecules 2020, 11, 42.
    24. Frederico, É.H.F.F.; Cardoso, A.L.B.D.; Moreira-Marconi, E.; de Sá-Caputo, D.D.C.; Guimarães, C.A.S.; Dionello, C.D.F.; Morel, D.S.; Paineiras-Domingos, L.L.; de Souza, P.L.; Brandão-Sobrinho-Neto, S.; et al. Anti-viral effects of medicinal plants in the management of dengue: A systematic review. Afr. J. Tradit. Complement. Altern. Med. 2017, 14, 33–40.
    25. Chan, Y.S.; Khoo, K.S.; Sit, N.W. Investigation of twenty selected medicinal plants from Malaysia for anti-Chikungunya virus activity. Int. Microbiol. 2016, 19, 175–182.
    26. Ledoux, A.; Cao, M.; Jansen, O.; Mamede, L.; Campos, P.E.; Payet, B.; Clerc, P.; Grondin, I.; Girard-Valenciennes, E.; Hermann, T.; et al. Antiplasmodial, anti-chikungunya virus and antioxidant activities of 64 endemic plants from the Mascarene Islands. Int. J. Antimicrob. Agents 2018, 52, 622–628.
    27. Weber, C.; Sliva, K.; von Rhein, C.; Kümmerer, B.M.; Schnierle, B.S. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antivir. Res. 2015, 113, 1–3.
    28. Mounce, B.C.; Cesaro, T.; Carrau, L.; Vallet, T.; Vignuzzi, M. Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding. Antivir. Res. 2017, 142, 148–157.
    29. Kaur, P.; Thiruchelvan, M.; Lee, R.C.; Chen, H.; Chen, K.C.; Ng, M.L.; Chu, J.J. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob. Agents Chemother. 2013, 57, 155–167.
    30. Maria John, K.M.; Harnly, J.; Luthria, D. Influence of direct and sequential extraction methodology on metabolic profiling. J. Chromatogr. B 2018, 1073, 34–42.
    31. Cowan, M.M. Plant products as antimicrobial agents. Clin. Microbiol. Rev. 1999, 12, 564–582.
    32. Thongnest, S.; Boonsombat, J.; Prawat, H.; Mahidol, C.; Ruchirawat, S. Ailanthusins A-G and nor-lupane triterpenoids from Ailanthus triphysa. Phytochemistry 2017, 134, 98–105.
    33. Shukri, R.; Mohamed, S.; Mustapha, N.M.; Hamid, A.A. Evaluating the toxic and beneficial effects of jering beans (Archidendron jiringa) in normal and diabetic rats. J. Sci. Food Agric. 2011, 91, 2697–2706.
    34. Zhang, X.; Chen, W.; Du, Y.; Su, P.; Qiu, Y.; Ning, J.; Liu, M. Phytochemistry and pharmacological activities of Arundina graminifolia (D.Don) Hochr. and other common Orchidaceae medicinal plants. J. Ethnopharmacol. 2021, 276, 114143.
    35. Saleem, S.; Muhammad, G.; Hussain, M.A.; Bukhari, S.N.A. A comprehensive review of phytochemical profile, bioactives for pharmaceuticals, and pharmacological attributes of Azadirachta indica. Phytother. Res. 2018, 32, 1241–1272.
    36. Deshmukh, S.A.; Gaikwad, D.K. A review of the taxonomy, ethnobotany, phytochemistry and pharmacology of Basella alba (Basellaceae). J. Appl. Pharm. Sci. 2014, 4, 153–165.
    37. Hamedi, S.; Honarvar, M. Beta vulgaris—A mini review of traditional uses in Iran, phytochemistry and pharmacology. Curr. Drug Discov. Technol. 2019, 16, 74–81.
    38. Kamarudin, M.N.A.; Sarker, M.M.R.; Kadir, H.A.; Ming, L.C. Ethnopharmacological uses, phytochemistry, biological activities, and therapeutic applications of Clinacanthus nutans (Burm. f.) Lindau: A comprehensive review. J. Ethnopharmacol. 2017, 206, 245–266.
    39. Ayati, Z.; Ramezani, M.; Amiri, M.S.; Moghadam, A.T.; Rahimi, H.; Abdollahzade, A.; Sahebkar, A.; Emami, S.A. Ethnobotany, phytochemistry and traditional uses of Curcuma spp. and pharmacological profile of two important species (C. longa and C. zedoaria): A review. Curr. Pharm. Des. 2019, 25, 871–935.
    40. Akah, P.A.; Orisakwe, O.E.; Gamaniel, K.S.; Shittu, A. Evaluation of Nigerian traditional medicines: II. Effects of some Nigerian folk remedies on peptic ulcer. J. Ethnopharmacol. 1998, 62, 123–127.
    41. Abe, R.; Ohtani, K. An ethnobotanical study of medicinal plants and traditional therapies on Batan Island, the Philippines. J. Ethnopharmacol. 2013, 145, 554–565.
    42. Bunawan, H.; Amin, N.M.; Bunawan, S.N.; Baharum, S.N.; Mohd Noor, N. Ficus deltoidea Jack: A review on its phytochemical and pharmacological importance. Evid. Based Complement. Alternat. Med. 2014, 2014, 902734.
    43. Teoh, W.Y.; Sim, K.S.; Moses Richardson, J.S.; Abdul Wahab, N.; Hoe, S.Z. Antioxidant capacity, cytotoxicity, and acute oral toxicity of Gynura bicolor. Evid. Based Complement. Altern. Med. 2013, 2013, 958407.
    44. Siriwatanametanon, N.; Fiebich, B.L.; Efferth, T.; Prieto, J.M.; Heinrich Michael, M. Traditionally used Thai medicinal plants: In vitro anti-inflammatory, anticancer and antioxidant activities. J. Ethnopharmacol. 2010, 130, 196–207.
    45. Hazarika, I.; Mukundan, G.K.; Sundari, P.S.; Laloo, D. Journey of Hydrocotyle sibthorpioides Lam.: From traditional utilization to modern therapeutics—A review. Phytother. Res. 2021, 35, 1847–1871.
    46. Lim, T.K. Edible Medicinal and Non-Medicinal Plants: Fruits; Springer Science + Business Media: Dordrecht, The Netherlands, 2013; Volume 6, pp. 110–118.
    47. Zengin, G.; Ferrante, C.; Gnapi, D.E.; Sinan, K.I.; Orlando, G.; Recinella, L.; Diuzheva, A.; Jekő, J.; Cziáky, Z.; Chiavaroli, A.; et al. Comprehensive approaches on the chemical constituents and pharmacological properties of flowers and leaves of American basil (Ocimum americanum L.). Food Res. Int. 2019, 125, 108610.
    48. Saleh, M.S.M.; Jalil, J.; Zainalabidin, S.; Asmadi, A.Y.; Mustafa, N.H.; Kamisah, Y. Genus Parkia: Phytochemical, medicinal uses, and pharmacological properties. Int. J. Mol. Sci. 2021, 22, 618.
    49. Farzaei, M.H.; Abbasabadi, Z.; Ardekani, M.R.S.; Rahimi, R.; Farzaei, F. Parsley: A review of ethnopharmacology, phytochemistry and biological activities. J. Tradit. Chin. Med. 2013, 33, 815–826.
    50. Saleh, M.S.M.; Siddiqui, M.J.; Mediani, A.; Ismail, N.H.; Ahmed, Q.U.; So’ad, S.Z.M.; Saidi-Besbes, S. Salacca zalacca: A short review of the palm botany, pharmacological uses and phytochemistry. Asian Pac. J. Trop. Med. 2018, 11, 645–652.
    51. Vieira, E.F.; Pinho, O.; Ferreira, I.M.P.L.V.O.; Delerue-Matos, C. Chayote (Sechium edule): A review of nutritional composition, bioactivities and potential applications. Food Chem. 2019, 275, 557–568.
    52. Zakaria, S.M.; Amri, C.N.A.C.; Shahari, R. Ethnobotany and traditional knowledge of Acanthaceae in Peninsular Malaysia: A review. Pharmacogn. J. 2020, 12, 1482–1488.
    53. Bernard, E.; Solignat, M.; Gay, B.; Chazal, N.; Higgs, S.; Devaux, C.; Briant, L. Endocytosis of chikungunya virus into mammalian cells: Role of clathrin and early endosomal compartments. PLoS ONE 2010, 5, e11479.
    54. Khan, M.; Santhosh, S.R.; Tiwari, M.; Lakshmana Rao, P.V.; Parida, M. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in Vero cells. J. Med. Virol. 2010, 82, 817–824.
    55. Bourjot, M.; Delang, L.; Nguyen, V.H.; Neyts, J.; Guéritte, F.; Leyssen, P.; Litaudon, M. Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of Chikungunya virus replication. J. Nat. Prod. 2012, 75, 2183–2187.
    56. Scholte, F.E.; Tas, A.; Martina, B.E.; Cordioli, P.; Narayanan, K.; Makino, S.; Snijder, E.J.; van Hemert, M.J. Characterization of synthetic Chikungunya viruses based on the consensus sequence of recent E1-226V isolates. PLoS ONE 2013, 8, e71047.
    57. Raghavendhar, S.; Tripati, P.K.; Ray, P.; Patel, A.K. Evaluation of medicinal herbs for Anti-CHIKV activity. Virology 2019, 533, 45–49.
    58. Sakdarat, S.; Shuyprom, A.; Pientong, C.; Ekalaksananan, T.; Thongchai, S. Bioactive constituents from the leaves of Clinacanthus nutans Lindau. Bioorg. Med. Chem. 2009, 17, 1857–1860.
    59. Kunsorn, P.; Ruangrungsi, N.; Lipipun, V.; Khanboon, A.; Rungsihirunrat, K. The identities and anti-herpes simplex virus activity of Clinacanthus nutans and Clinacanthus siamensis. Asian Pac. J. Trop. Biomed. 2013, 3, 284–290.
    60. Sookmai, W.; Ekalaksananan, T.; Pientong, C.; Sakdarat, S.; Kongyingyoes, B. The anti-papillomavirus infectivity of Clinacanthus nutans compounds. Srinagarind Med. J. 2011, 26, 240–243.
    61. Tu, S.-F.; Liu, R.H.; Cheng, Y.-B.; Hsu, Y.-M.; Du, Y.-C.; El-Shazly, M.; Wu, Y.-C.; Chang, F.-R. Chemical constituents and bioactivities of Clinacanthus nutans aerial parts. Molecules 2014, 19, 20382–20390.
    62. Husin, F.; Chan, Y.Y.; Gan, S.H.; Sulaiman, S.A.; Shueb, R.H. The effect of Hydrocotyle sibthorpioides Lam. extracts on in vitro dengue replication. Evid. Based Complement. Altern. Med. 2015, 2015, 596109.
    63. Huang, Q.; Zhang, S.; Huang, R.; Wei, L.; Chen, Y.; Lv, S.; Liang, C.; Tan, S.; Liang, S.; Zhuo, L.; et al. Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides Lam. J. Ethnopharmacol. 2013, 150, 568–575.
    64. Yucharoen, R.; Anuchapreeda, S.; Tragoolpua, Y. Anti-herpes simplex virus activity of extracts from the culinary herbs Ocimum sanctum L., Ocimum basilicum L. and Ocimum americanum L. Afr. J. Biotechnol. 2011, 10, 860–866.
    65. Hanisa, H.; Mohd Azmi, M.L.; Suhaila, M.; Somchit, M.N. In vitro anti-viral activity of Centella asiatica L., Curcuma longa L. and Strobilanthes crispus L. against herpes virus. Int. J. Pharma Bio Sci. 2014, 5, B42–B52.
    66. Mouhajir, F.; Hudson, J.B.; Rejdali, M.; Towers, G.H.N. Multiple antiviral activities of endemic medicinal plants used by Berber peoples of Morocco. Pharm. Biol. 2001, 39, 364–374.
    More